Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations · 26.5M shares · +59%/yr ↑ dilution · EDGAR filings ↗
Reference price $5.72 · est. market cap ~$152M — last insider purchase, 2025-11-05 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D42Clinical/early-stage biotech — oncology clinical micro-cap, funded.
Strengths
- Liquidity — current ratio 2.4 (31st)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +59%/yr over 3y (dilution, book value/share -68%)
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
Key metrics
Return on equity
-143.6%
Return on assets
-83.4%
Current ratio
2.4×
Tangible book value
$18M
Cash & investments
$32M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-11 | Sanchez Juan | Grant | 35K | — |
| 2026-06-11 | Oliviero James F III | Grant | 35K | — |
| 2026-06-11 | Hoberman Kenneth | Grant | 35K | — |
| 2026-06-11 | Kaplan Matthew L. | Grant | 35K | — |
| 2026-01-06 | Shemesh Shay | Grant | 150K | — |
| 2026-01-06 | BENTSUR RON | Grant | 150K | — |
| 2026-01-06 | Poradosu Enrique | Grant | 150K | — |
| 2026-01-06 | Carson Michael J. | Grant | 61K | — |
| 2025-11-05 | Sanchez Juan | Buy | 13K | $5.79 |
| 2025-11-05 | BENTSUR RON | Buy | 5.0K | $5.72 |
| 2025-11-05 | Kaplan Matthew L. | Buy | 11K | $5.84 |
| 2025-10-27 | Mosseri Marlio Charles | Buy | 73K | $6.28 |
| 2025-10-24 | Mosseri Marlio Charles | Buy | 35K | $6.15 |
| 2025-10-23 | Mosseri Marlio Charles | Buy | 47K | $6.06 |
| 2025-09-22 | Sanchez Juan | Grant | 30K | — |
| 2025-06-20 | Mosseri Marlio Charles | Buy | 5.6K | $7.99 |
| 2025-06-18 | Mosseri Marlio Charles | Buy | 28K | $8.05 |
| 2025-06-17 | Mosseri Marlio Charles | Buy | 5.4K | $8.11 |
| 2025-06-12 | Hoberman Kenneth | Grant | 30K | — |
| 2025-06-12 | Kaplan Matthew L. | Grant | 30K | — |
| 2025-06-12 | Oliviero James F III | Grant | 30K | — |
| 2025-05-12 | Mosseri Marlio Charles | Buy | 21K | $8.11 |
| 2025-05-09 | Mosseri Marlio Charles | Buy | 9.8K | $8.90 |
| 2025-05-09 | Mosseri Marlio Charles | Buy | 9.8K | $8.95 |
| 2025-05-09 | Mosseri Marlio Charles | Buy | 5.4K | $8.98 |
| 2025-05-08 | Mosseri Marlio Charles | Buy | 100 | $8.99 |
| 2025-05-08 | Mosseri Marlio Charles | Buy | 50 | $8.65 |
| 2025-05-08 | Mosseri Marlio Charles | Buy | 100 | $8.65 |
| 2025-05-08 | Mosseri Marlio Charles | Buy | 2.4K | $8.65 |
| 2025-05-08 | Mosseri Marlio Charles | Buy | 100 | $8.65 |
| 2025-05-08 | Mosseri Marlio Charles | Buy | 100 | $8.71 |
| 2025-05-08 | Mosseri Marlio Charles | Buy | 2.4K | $8.97 |
| 2025-05-07 | Mosseri Marlio Charles | Buy | 9.6K | $8.64 |
| 2025-05-07 | Mosseri Marlio Charles | Buy | 2.7K | $8.40 |
| 2025-05-06 | Mosseri Marlio Charles | Buy | 10K | $8.64 |
| 2025-05-06 | Mosseri Marlio Charles | Buy | 2.3K | $8.40 |
| 2025-02-07 | Mosseri Marlio Charles | Buy | 240K | $5.00 |
| 2025-01-02 | Shemesh Shay | Grant | 150K | — |
| 2025-01-02 | Poradosu Enrique | Grant | 150K | — |
| 2025-01-02 | Carson Michael J. | Grant | 51K | — |
| 2025-01-02 | BENTSUR RON | Grant | 250K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05873686 ↗ | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer) | PHASE1 | Recruiting | 2027-03-01 |
| NCT07315113 ↗ | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients | PHASE1 | Recruiting | 2026-12-01 |
| NCT05226507 ↗ | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer Advanced Solid Tumor, Ovarian Cancer | PHASE1 | Active Not Recruiting | 2025-12-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-23 | Material agreementOtherExhibits | filing ↗ |
| 2026-06-12 | Shareholder vote | filing ↗ |
| 2026-05-05 | ResultsExhibits | filing ↗ |
| 2026-02-11 | ResultsExhibits | filing ↗ |
| 2025-11-04 | ResultsExhibits | filing ↗ |
| 2025-09-25 | Exec/director changeExhibits | filing ↗ |
| 2025-08-05 | ResultsExhibits | filing ↗ |
| 2025-06-13 | Shareholder vote | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-23 | 2026-06-22 | 0001104659-26-076624 ↗ |
| 8-K | 2026-06-12 | 2026-06-11 | 0001104659-26-073419 ↗ |
| 10-Q | 2026-05-05 | 2026-03-31 | 0001104659-26-055318 ↗ |
| 8-K | 2026-05-05 | 2026-05-05 | 0001104659-26-055264 ↗ |
| 10-K | 2026-02-11 | 2025-12-31 | 0001104659-26-013044 ↗ |
| 8-K | 2026-02-11 | 2026-02-11 | 0001104659-26-013049 ↗ |
| 10-Q | 2025-11-04 | 2025-09-30 | 0001104659-25-105939 ↗ |
| 8-K | 2025-11-04 | 2025-11-04 | 0001104659-25-105953 ↗ |
| 8-K | 2025-09-25 | 2025-09-22 | 0001104659-25-093144 ↗ |
| 8-K | 2025-08-05 | 2025-08-05 | 0001104659-25-073967 ↗ |
| 10-Q | 2025-08-05 | 2025-06-30 | 0001558370-25-010203 ↗ |
| 8-K | 2025-06-13 | 2025-06-12 | 0001104659-25-059435 ↗ |